Navigation Links
Labopharm submits response to FDA for novel antidepressant
Date:8/11/2009

LAVAL, QC, Aug. 11 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has submitted its response to the U.S. Food and Drug Administration's (FDA) complete response letter regarding the Company's novel formulation of the antidepressant trazodone.

As previously announced, Labopharm received a complete response letter from the FDA on July 17, 2009 indicating the Company's new drug application (NDA) for its novel trazodone formulation could not be approved in its present form due to deficiencies following the FDA's inspection of the active pharmaceutical ingredient (API) manufacturing facility. The letter did not raise any efficacy or safety issues.

The FDA is expected to notify Labopharm within 14 days as to whether or not the Company's response has been accepted for review. Once accepted and in accordance with the Prescription Drug User Fee Act (PDUFA), the FDA will assign Labopharm a new action date.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets and Australia. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review in the U.S. by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www.labo
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Soft and synthetic red-blood-cell-like particles carry oxygen, drugs, and more… ... ... -- Scientists at UC Santa Barbara, in collaboration with scientists ... mimic the characteristics and key functions of natural red blood ... , , , , ,The primary function of natural ...
(Date:12/14/2009)... Heska Corporation (Nasdaq: HSKA ; "Heska" ... veterinary diagnostic and specialty products, today announced ... new DRI-CHEM® 7000 Veterinary Chemistry Analyzer (the ... ,, Customers receiving these analyzers have invested ... available to the veterinary in-clinic market. ...
(Date:12/14/2009)... Enough To Wear Pink(TM) (TETWP), the grassroots cowboy ... anniversary at the signature Tough Enough To Wear ... (Wrangler NFR) in Las Vegas. While pink is ... support of the western industry and rodeo fans ... shirts, hats, bracelets and more. ,, Through ...
(Date:12/14/2009)... widely and are higher than generally thought, raising concerns about increased ... of California, San Francisco (UCSF) imaging specialists. , ... ... doses from common CT procedures vary widely and are higher than ... a new study led by University of California, San Francisco ...
(Date:12/14/2009)... The Hemophilia Federation of America (HFA) expresses its ... Teamsters Local 929 and the American Red Cross ... depends on skilled workers to provide clean, safe ... products such as clotting factor for use in ... The Division of Blood Services at the American ...
Breaking Medicine News(10 mins):Health News:Synthetic Red Blood Cells Developed 2Health News:Synthetic Red Blood Cells Developed 3Health News:Heska Announces Installation of New Chemistry Analyzer 2Health News:Heska Announces Installation of New Chemistry Analyzer 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5Health News:HFA Voices Blood Safety Concerns 2
... Smokers who have a say in how they quit are ... successful, according to new research at the University of Rochester ... of medicine at the University of Rochester School of Medicine ... this month that demonstrate patient involvement in a quit plan ...
... too. Together, they form a difficult pair to beat ... team of Ohio University College of Osteopathic Medicine (OU-COM) ... approach to the double-edged problem. Program ACTIVE (Appalachians Coming ... feasibility study to test the effectiveness of a combination ...
... by Huibert Mansvelder reveals that a stimulating environment can restore ... findings have been published in the May 24, 2007 issue ... ,A type of inherited mental retardation; Fragile X syndrome affects ... females. The researchers carried out studies on mice that were ...
... Dr. Lin Mei report in the May 24 issue ... keep a healthy balance between excitation and inhibition ... in cancer and schizophrenia. ,The research showed ... the site of inhibitory synapses in the brain by ...
... new study in The Journal of Strength and Conditioning ... experience a lowered response to resistance training when ... compared the response to a supervised upper arm, unilateral ... overweight or obese to the response of normal weight ...
... Mark Heiner of Culver City reads books, paints artistically, ... be considered routine except for the fact that ... keeping his blood flowing. ,The procedure to ... March by a team led by cardiothoracic surgeon Sinan ...
Other Medicine News:Health News:Choice is a Key Element in Success for Smokers Who Want to Quit 2Health News:Study Tests Depression Treatment for Diabetes Patients 2Health News:Study Tests Depression Treatment for Diabetes Patients 3Health News:Enriching Environment Stimulates Neurons: Hope For Fragile X Syndrome 2Health News:Brain Cells Activity: New Treatment Target for Psychiatric Diseases 2Health News:Brain Cells Activity: New Treatment Target for Psychiatric Diseases 3Health News:Heart-Assist Device Gives Culver City Man a Good Quality of Life 2Health News:Heart-Assist Device Gives Culver City Man a Good Quality of Life 3
(Date:12/14/2009)... THE WOODLANDS, Texas, Dec. 14 /PRNewswire/ ... investigators affiliated with US Oncology ... were presented orally at the ... , held Dec. 9-13 at the ... in San Antonio, Texas . ...
(Date:12/14/2009)... Cardinal Health today announced that executives of ... ,, Goldman Sachs CEO Unplugged Conference ... Sachs Conference Center in New York. 28th ... at Noon EST at the Westin St. Francis Hotel ... executives will discuss Cardinal Health,s diverse products and services, ...
(Date:12/14/2009)... Southridge LLC ("Southridge"), an investment firm that provides ... announce that its affiliated fund has closed a private ... equity financing to Imaging Diagnostic Systems, Inc. (OTCBB: IMDS). ... growth of Imaging Diagnostic Systems, Southridge has paved a ... the field of early breast cancer detection," said Stephen ...
Breaking Medicine Technology:US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 2US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 4US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 5US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 6US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 7US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 8US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 9Cardinal Health Executives to Speak at Two Investor Events in January 2Southridge LLC Provides Funding Through Private Equity Agreement with Imaging Diagnostic Systems, Inc. 2Meda Introduces EDLUAR 28TM 29 the First and Only Sublingual Tablet That Contains the Most Prescribed Sleep Medication Zolpidem Tartrate 56404 1Meda Introduces EDLUAR 28TM 29 the First and Only Sublingual Tablet That Contains the Most Prescribed Sleep Medication Zolpidem Tartrate 56404 2Meda Introduces EDLUAR 28TM 29 the First and Only Sublingual Tablet That Contains the Most Prescribed Sleep Medication Zolpidem Tartrate 56404 3Meda Introduces EDLUAR 28TM 29 the First and Only Sublingual Tablet That Contains the Most Prescribed Sleep Medication Zolpidem Tartrate 56404 4Delta Health an InfoLogix Company Wins Engagement with Hennepin County Medical Center for Strategic Cost Management 56400 1Delta Health an InfoLogix Company Wins Engagement with Hennepin County Medical Center for Strategic Cost Management 56400 2Delta Health an InfoLogix Company Wins Engagement with Hennepin County Medical Center for Strategic Cost Management 56400 3Genova files patent for new prostate cancer treatment 56395 1Genova files patent for new prostate cancer treatment 56395 2
... at AASLD annual meeting, Pivotal Phase III ... failed prior treatment, SAN FRANCISCO, Nov. 1 ... that a planned interim analysis of a,Phase II ... C,protease inhibitor, in combination with peginterferon and ribavirin,markedly ...
... I Clinical Data and Additional Preclinical Results for Non-Nucleoside ... Polymerase Inhibitor Being Presented at AASLD, SAN DIEGO, Nov. ... the results of a Phase I clinical trial,of ANA598 in ... of the leading non-nucleoside polymerase inhibitors,currently in development for the ...
Other Medicine Technology:Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 3Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 4Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 5Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 6Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 7Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 8Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 9Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 10Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers 2Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers 3Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers 4Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers 5Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers 6
The dryer is designed to rapidly dry slides by blowing warm air over the surface of the slides. The slide dryer accommodates two slide racks directly from a stainer and allows the slides to be staine...
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
... have a positive and negative inoculated well, ... these slides, perform QC and sample staining ... education and training programs by testing QC ... on one slide! KWIK-QC slides contain the ...
... Well Plate Capability The Equalizer 384 ... Equalizerexpandable and equal tip spacing, choice of two ... In addition, this model allows you to evenly ... and accessing many gels and for use with ...
Medicine Products: